Sparsentan in Posttransplant Immunoglobulin A Nephropathy or Focal Segmental Glomerulosclerosis
Summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
- Radko Komers, MD, PhD
Travere Therapeutics
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
8 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- University of Alabama at Birmingham
Birmingham, Alabama, United States
- Cornell Medical Center
New York, New York, United States
- University of North Carolina Chapel Hill
Morrisville, North Carolina, United States
- Ohio State University
Columbus, Ohio, United States
- Dallas Nephrology Associates
Dallas, Texas, United States
- University of Texas
Galveston, Texas, United States
- University of Washington
Seattle, Washington, United States
- University of Wisconsin
Madison, Wisconsin, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 7 Oct 2025
- Primary completion
- 31 Mar 2027
- Completion
- 31 May 2027
- Last update posted
- 23 Jun 2026
- Registered enrollment
- 20
- Registry id
- NCT07219121
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 4 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.